Advertise on podcast: The Dime

Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise. The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge. This week we sit down with Jay Rosenthal Limbo as a moatEU GMP advantageRegulation's hidden winnersChapters00:00 Federal limbo becomes the business model02:17 The reform everyone agrees on03:28 Capital markets and the bigger pond05:35 Six hundred brands and no patience06:55 Why Rochester can move New York09:48 Strong operators become obvious13:40 The cost of crossing state lines16:28 Aurora Curaleaf and scarce EU GMP assets20:26 The Canadian future that did not arrive22:00 What mature industry compliance could bring24:35 Cultivated's nonsecret sauce31:41 Cannabis stigma still follows the operator32:28 Why Cultivated launched membership40:23 Quality media has a real cost41:18 California and New York regulators share a market44:02 Policy goals that fight each other49:06 Competition cooperation and price compression52:25 Where to find Jay and CultivatedGuest LinksJay Rosenthal - Co-Founder and Managing Director of Cultivated MediaCultivated MediaCultivated eventsSign up for the Cultivated Daily newsletterOur LinksThe Dime Podcast — websiteBryan Fields on XThe Dime on XThe Dime on YouTubeThe Dime on InstagramNewton Insights — insights for extraction teamsFollow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator rethinking their edibles. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time. This week we sit down with Kim Sanchez Rael Fast onset economicsThe nano problemScience/ AI and so much more Fast-acting cannabis edibles promise a more predictable experience, but the language on the package does not always tell operators what happens in the final product. Kim Sanchez Rael, President and CEO of Azuca, breaks down what "fast" should mean, why slow-onset edibles still dominate, and how formulation choices affect taste, stability, curing time, shelf life, and production efficiency. She explains why "nano" is often a measurement or marketing label rather than proof of a better consumer outcome, then offers four questions brands should ask any infusion supplier. The conversation also moves beyond formulation. Kim describes the economics behind fast-acting products, the role of supplier behavior when production is at risk, the case for a single regulatory framework for the cannabis plant, and why operators cannot build a business that depends on an unpredictable regulatory change. Topics include: The consumer value of predictable onsetManufacturing tradeoffs in gummy formulationWhat brands should demand from infusion partnersWhy structured quality systems matterHow Azuca uses AI inside its team and customer experienceLearn more about Azuca and TiME INFUSION® at https://azuca.co/. Guest: Kim Sanchez Rael, President and CEO, AzucaHost: Bryan Fields, The Dime Chapters 00:01 Why slow-onset edibles still dominate01:47 The economics of fast acting03:56 Can brands claim "fast"?05:56 Predictability and consumer trust08:06 The retail education gap10:24 How Azuca licensing works14:44 Formulation, cannabinoids, and flavor15:30 When "fast" does not feel fast18:18 Onset, peak, and duration20:01 Manufacturing efficiency R&D23:14 Validating infusion science24:43 Why "nano" is a buzzword27:38 The operational cost of change28:24 Four questions for infusion suppliers30:00 Supplier behavior as brand experience32:31 The Fourth of July production rescue33:48 What cannabis still gets wrong34:15 The One Plant Solution37:04 Policy resistance and incrementalism38:41 AI and "Kimothy"41:21 Quality systems and sustainable math44:58 The question Kim wishes people asked45:45 Where to find AzucaOur Links The Dime Podcast — websiteBryan Fields on XThe Dime on XThe Dime on YouTubeThe Dime on InstagramEighth RevolutionNewton Insights — insights for extraction teamsFollow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator rethinking their edibles. Guest Links Kim Sanchez Rael — Azuca Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Global expansion is often pitched as an opportunity. For an undisciplined cannabis company, it is an expensive way to expose every weakness at once. International markets reward specific operating capabilities, not ambition alone. Pharmaceutical standards, reliable supply, disciplined data use, and local market fit determine whether an operator can cross borders without compounding its problems. This week we sit down with Jamie Pearson EU GMP's undervalued strategic valueRegulation exposes operating weaknessMatching strength to global marketsOn The Dime, host Bryan Fields speaks with Jamie L. Pearson, President and Founder of New Holland Group, about European cannabis expansion, medical cannabis supply chains, and building operations that can succeed across borders. Key TakeawaysJamie explains why European medical cannabis markets call for pharmaceutical reliability, consistent supply, and a different operating model from adult-use brands.EU GMP (European Union Good Manufacturing Practice) capability can be a strategic asset for cannabis manufacturing and international market entry.Match the company's repeatable strengths to local buyers, regulations, and supply chains before choosing a market.Prove standard operating procedures (SOPs) and quality controls in another U.S. state before adding language, currency, and cross-border complexity.The discussion spans the UK, Germany, Switzerland, Slovenia, Portugal, and Brazil, alongside cannabis data and U.S. hemp regulation.Chapters00:00 Regulation is breaking the data layer02:49 Finding trend data upstream06:24 What EU GMP actually demands10:19 Why compliant facilities become strategic assets16:13 Canada-Europe regulatory harmony19:20 Europe is medical first25:28 First-mover advantage vs. disciplined execution27:59 Medical supply rewards repeatability30:48 Weak operations do not travel32:24 Switzerland, Slovenia, and Portugal35:54 Brazil and partner requirements37:07 Practice expansion before global scale40:08 The hidden U.S. hemp market43:29 Turning customers into political force47:10 Directness as respect Guest LinksJamie L. Pearson — official bioNew Holland GroupNew Holland Group on LinkedInRelated EpisodeGermany Is the Engine: What BAT Knows That Cannabis Doesn't ft. James Yamanaka — continue exploring Germany's cannabis market and operational discipline. Our LinksThe Dime Podcast — websiteBryan Fields on XThe Dime on XThe Dime on YouTubeThe Dime on InstagramEighth RevolutionNewton Insights — insights for extraction teamsFollow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator considering expansion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Much of the licensed cannabis industry is quietly counting the volume it expects to inherit from the federal hemp ban coming this November. ** Now December. What they may not realize is that the ban could eliminate the full-spectrum therapeutic hemp formulations that helped change America's view of cannabis and are used daily by an estimated 45 million Americans. The provision was written by two members of Congress, without a conference or regular order, and inserted into a massive spending bill during the longest government shutdown in American history. What should have been handled with a scalpel was done with a sledgehammer. This week we sit down with Paige Figi to discuss • Silence is a position • The scalpel Congress skipped • Oval Office, then banned Chapters 00:00 Introduction to the legislative landscape of cannabis 00:21 The impact of Charlotte's story on cannabis perception 00:48 Distinguishing hemp from marijuana in legislation 02:11 The challenges of passing therapeutic hemp laws 02:52 Congress's need for simple, effective regulation 03:48 The slow progress of therapeutic hemp legalization 04:53 The importance of clear plant distinctions 05:56 The November 12 hemp ban and its implications 07:02 The dangers of Franken hemp and synthetic cannabinoids 08:00 The public health emergency posed by recent bans 08:49 The role of science and data in regulation 10:13 The importance of industry and public unity 10:58 How regulations can support medical and adult use 12:06 The impact of federal bans on patients and consumers 13:00 The need for a balanced, science-based approach 14:00 The political landscape and legislative hurdles 14:53 The power of public advocacy and individual action 16:07 The future of cannabis regulation and industry alignment 17:06 How to effectively communicate with policymakers 18:03 The importance of clear, science-backed legislation 19:00 The role of the FDA and federal agencies 20:01 The potential for bipartisan support and progress 21:08 The significance of the November 12 deadline 22:06 The ongoing fight for access and regulation 23:04 The moral and ethical considerations in cannabis policy 23:49 How consumers can influence policy change 24:47 The importance of unity within the industry 25:46 The potential for a balanced, effective regulatory framework 27:06 The role of science and data in shaping policy 28:03 The need for responsible, clear regulations 29:02 The future outlook for therapeutic hemp and CBD 30:02 Final thoughts and call to action Guest Links https://www.coalitionforaccess.org/ https://www.instagram.com/paigefigi/ https://realmofcaring.org/about/paige-figi/ Our Links Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

AI has made software easier than ever to build. That does not mean every internal tool should become the backbone of your business. In this episode, Bryan sits down with Chris Guthrie to break down the growing temptation inside cannabis companies to vibe code internal tools, dashboards, CRMs, ERPs, and operational systems in the name of saving money. The problem is not the first version. The problem is what happens two months later, when a field does not map, the workflow breaks, the person who built it is unavailable, and a production team is now relying on code nobody fully understands. Chris explains the difference between a useful AI-built prototype and an enterprise-grade system that can survive real operators, messy data, security needs, compliance, multiple departments, M&A diligence, and future FDA-style requirements. This conversation covers why descriptive data does not create predictive insight, why Google Sheets to vibe coding can become a path to failure, and why the real AI opportunity starts after the business has clean data, clean processes, and a system strong enough to trust. This episode covers: The weekend build that fails Descriptive data will not predict Clean books before M&A Chapters   00:00 The Rise of AI in Software Development 03:07 Challenges of Internal Software Development 06:09 Understanding What 'Works' in Software 09:10 The Risks of Vibe Coding 12:05 The Importance of Established Infrastructure 14:58 Cost Considerations in Software Development 17:56 Predictive Insights and Data Utilization 21:13 Defining Core Business Focus 23:17 The Challenges of AI Implementation 27:00 Understanding AI's Limitations 28:58 The Importance of Data Governance 31:11 Navigating Change Management in Cannabis 35:51 Preparing for Industry Evolution 40:09 The ROI of ERP Systems Our Links: Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cannabis rescheduling is not as simple as “Trump rescheduled cannabis.” States are interpreting rescheduling completely differently depending on their license structure. These tiny details are widening the gap between potential winners and losers. In this episode, we break down what actually changed, what is still unresolved, and why rescheduling may already be picking winners and losers. This week, we sit down with Hirsh Jain to discuss: • What the April order and June 29 hearing actually mean • How the DEA registration portal could impact operators • The three pathways for interstate commerce • Why state license structure may determine who is positioned for a national market   Chapters 00:00 Understanding Cannabis Rescheduling 02:53 The Implications of Medical vs. Adult Use Cannabis 05:48 Navigating Federal Legality for Medical Cannabis 09:03 DEA Registration: A New Era for Cannabis Businesses 11:53 The Complexities of DEA Registration 15:02 Interstate Commerce: The Future of Cannabis Trade 17:46 State Models and Their Impact on Cannabis Regulation 21:02 Winners and Losers in the Cannabis Market 24:04 The Role of Politics in Cannabis Regulation 27:01 The Future of Interstate Commerce in Cannabis 38:15 Understanding the Dormant Commerce Clause 40:46 Interstate Commerce and Political Friction 42:43 Legal Challenges to Cannabis Rescheduling 44:37 The April Order and Its Implications 51:05 Upcoming Hearings and Their Significance 59:22 Emerging Markets in Red States 01:05:34 Cultural Shifts and Legal Implications 01:10:16 Looking Ahead: Signals for Progress Guest Links: https://www.anandastrategy.com/ Our Links: Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Predictable cash flow is the whole game. In cannabis, predictable is the one thing almost nobody has. Organigram CEO James Yamanaka came up over 20 years at British American Tobacco, where that discipline is the entire model. He thinks the opportunity starts there: trim the portfolio, stop chasing every trend, tighten the supply chain, lean on the science, and align operations. Germany's market could nearly double in the next two years, but capturing it will take more than expansion. This week we sit down with James Yamanaka, CEO of Organigram: A BAT perspective on cannabis Why chasing every trend loses money How the Sanity deal unlocks Germany Chapters: 00:00 Introduction to Organigram and BAT's Involvement 05:24 Shifting Perspectives: From BAT to Organigram 09:08 Understanding the Complexity of the Cannabis Market 13:12 Balancing Listening and Leadership 17:24 Data-Driven Decision Making in Cannabis 21:18 Strategic SKU Management and Market Forecasting 24:17 Leveraging BAT's Expertise in Cannabis 30:04 The Strategic Importance of the Sanity Deal 39:57 Navigating Regulatory Challenges in the Cannabis Industry Guest Links: https://www.linkedin.com/in/james-yamanaka-aaa32a/ https://www.organigram.ca/ Our Links: Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

When a regulator asks what the downside is of adding one more testing requirement, what is the downside? Just a little more safe. Just in case. Especially when adding one more item to an already exhaustive testing panel. That logic is how licensed cannabis markets end up buried under compliance layers copied from other states, calibrated to someone else's problems. It is also exactly how two adjacent markets with nearly identical consumer bases, Ohio and Michigan, ended up with completely different market structures.  What they do not share is regulatory philosophy. When one state watches another add a rule and asks itself whether it should do the same, the answer it lands on shapes the entire cost structure of every licensed operator inside its borders. Ohio learned to ask the follow-up question. Most states never do. Ohio closed the intoxicating hemp loophole on March 20th, ahead of the federal government, and those shops are starting to close. The next unlock may already be here: THC beverages reaching the customers who will never walk into a dispensary, sold at the restaurant down the street. This week we sit down with Caroline Henry, VP of Government and Regulatory Affairs at Buckeye Relief. The regulator FOMO problem Ohio vs. Michigan: two markets, one lesson THC beverages as the dispensary gateway     Chapters 00:00 The Disconnect in Cannabis Perception 03:12 Navigating Stigma and Misconceptions 05:48 Regulatory Challenges and Industry Standards 08:55 Building Relationships with Regulators 11:54 Small Wins in Regulatory Negotiations 15:02 The Impact of Over-Regulation 17:48 Child-Resistant Packaging and Its Irony 25:38 Navigating Regulatory Challenges in the Cannabis Industry 26:00 The Role of Beverages in Reducing Stigma 30:37 Learning from Michigan: Ohio's Cannabis Strategy 39:31 Focusing on Ohio: The Case for Local Expertise 44:00 The Realities of Working in the Cannabis Industry   Guest Links www.buckeyerelief.com www.amplifydispensary.com Our Links: Bryan Fields on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The cannabis industry convinced the world it had a medicine before the science caught up. Now the science is here, and almost no one is paying attention. CBD is not a panacea. When Charlotte's Web opened hearts and minds, the messaging of what it could do ran years ahead of what the data could actually support. That gap created a backlash the legitimate medical thesis didn't deserve. What's left on the other side of the green rush is a near-complete forgetting of the reason this industry started in the first place. The medicine. Now the infrastructure to prove it is finally in place. Standardized genetics. Reproducible extraction. Full compound characterization. An FDA botanical drug pathway that has existed since 2016 that most investors have never heard of. Organic medicine versus synthetic single-molecule will be a real choice at the pharmacy counter sooner than most people expect. The foundational work is already here. This week we sit down with Joel Stanley and Dr. Marcel Bonn-Miller: Botanical drugs vs. supplements 6,000 compounds, one drug Novel compounds nobody has named yet Chapters 00:00 Why Medical Validation Remains a Challenge for Cannabis 00:12 The FDA Approval Process for Plant-Based Medicines 01:03 Historical Market Dynamics and Their Impact on Cannabis Perception 02:48 Removing the Veil: How Science Can Validate Cannabinoid Therapies 03:15 The Complexity of Plant Molecules and Real-World Evidence 06:20 Focus in Drug Development: The Case of Autism Spectrum Disorder 07:10 The Impact of Charlotte's Web and Media Hype 08:52 Balancing Hype and Reality in Cannabinoid Medicine 10:01 Legitimization of Cannabis Research in Academia 12:10 The Evolution of Cannabis Research and Acceptance 13:54 The Future of Botanical Medicine and Academic Research 16:15 The Long Road of Drug Development for Cannabis-Based Medicines 20:50 Introducing AJA-001: A Botanical Drug for Autism 22:44 Standardization and Characterization of Botanical Drugs 24:01 Partnerships and Funding in Botanical Drug Development 24:40 Challenges of Multi-Compound Botanical Drugs 27:28 Reproducibility and Quality Control in Botanical Manufacturing 29:06 FDA Pathways for Botanical Drugs and New Chemical Entities 34:29 Identifying and Characterizing Thousands of Plant Compounds 39:48 The Role of AI and Supercomputing in Drug Discovery 41:11 Balancing Exploration and Focus in Botanical Research 44:38 What the World Will Understand About Cannabinoids in 10 Years 47:24 The Promise of Botanical Medicine Over Single Molecule Drugs Guest Links: AJNA Biosciences Websitehttps://ajnabiosciences.com/ AJNA Biosciences LinkedInhttps://www.linkedin.com/company/ajna-biosciences/posts/?feedView=all AJNA Biosciences Instagram @ajnabiosciences Charlotte’s Web Websitehttps://www.charlottesweb.com/ Charlotte’s Web LinkedInhttps://www.linkedin.com/company/charlottesweb/posts/?feedView=all Charlotte’s Web Instagram @charlotteswebcbd Joel Stanley LinkedInhttps://www.linkedin.com/in/joel-stanley-2885116b/ Joel Stanley Instagram @joel.stanley Dr. Marcel Bonn-Miller LinkedInhttps://www.linkedin.com/in/marcel-bonn-miller-897a581/ Our Links: Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The number in your head and the number you actually need are not the same number. That gap is where most cannabis businesses break. Joe Lustberg has financed operators across the country for years and watched that gap swallow businesses that looked fine on paper. He has also spent over two years paying rent on a Hamptons dispensary he cannot open because a municipality tried to rezone his property out from under him. The person telling you to build in 1.5X as your burn capital cushion has been living inside exactly the scenario he warns everyone about. When the lender financing your industry has lived the same nightmare, the advice changes. This week we sit down with Joe Lustberg,  to discuss the following  NY Regulatory Battlefield 280E Gone: What Changes Lending Specifics   Chapters 00:00 Navigating the Cannabis Landscape: A Personal Journey 02:51 Understanding the Financial Risks in Cannabis Operations 06:01 The Importance of Burn Capital for Cannabis Startups 09:02 Lending Dynamics in the Cannabis Industry 11:55 Market Trends and the Future of Cannabis Financing 14:51 The Impact of Rescheduling on Cannabis Operators 18:01 Identifying Strong Operators in a Competitive Market 21:05 Evaluating Financial Health: Key Indicators for Success 26:01 Evaluating Limited Markets: The Ohio Perspective 28:24 Navigating Unique Financing Requests 29:12 Surprising Success Stories in Cannabis Financing 32:04 The Importance of Experience in New Ventures 35:46 Identifying Undervalued Markets in Cannabis 38:00 The Future of Cannabis Markets and Interstate Commerce Guest Links https://www.linkedin.com/in/joseph-lustberg-23076722 Our Links: Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cannabis operators aren't short on data. They're drowning in it. The real problem is what happens when that data gets handed to the wrong person, read at the wrong time, or used to justify the wrong decision. Overproduction cycles, steep discounting, margin pressure building back into manufacturing: most of that traces back to data being used reactively instead of as a decision guidance tool. Layer on the reality of multi-state operations where every market runs a different system, tracks different items, and reports differently. Making sense of what the numbers are actually saying across that footprint isn't just a technology problem. It's an interpretation problem with real financial consequences. Think of it like a compass that's slightly off calibrated. Over a short distance, no one notices. Across 15 facilities and hundreds of SKUs, you end up miles from where you intended. This week we sit down with Braunz Muller, to discuss the following  Margins in Cannabis Supply Chains Hydrocarbon SOP Secrets THC Efficiency as the Real KPI Chapter 00:00 Data Problems in Cannabis Manufacturing 12:50 The Complexity of Decision-Making 20:31 Dynamic SOPs in Extraction 30:14 Balancing Flexibility and Control in Operations 32:08 Empowering Operators Within Structured Systems 35:03 The Importance of Data in Extraction 39:27 Understanding Yield and Efficiency 43:00 Closing the Loop in Extraction Processes 48:40 Optimizing Cultivation for Better Efficiency 54:04 Auditing for Efficiency in Manufacturing 56:51 The Future of Hydrocarbon Extraction Knowledge   Guest Links: linkedin.com/in/braunz-muller-98382018b   Our Links: Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A customer walks into the dispensary and asks the budtender for a flower recommendation. They end up with a degraded version of the once high-end flower that graced your cultivation floor. They do not know it. Your brand took the blame. Ed Rosenthal, the most referenced name in cannabis cultivation history, says the cannabis supply chain has a freshness problem that starts in the dry room and compounds at every handoff. The smell of your drying room that everyone loves walking into? Those are your terpenes leaving the building. This week we sit down with Ed Rosenthal and Greg Baughman to discuss: How Canada already solved this Why most are still cultivating wrong Freeze drying vs. traditional drying Chapters 00:00 The Freshness Debate: Cannabis vs. Produce 03:01 Consumer Awareness and Dispensary Practices 05:55 Post-Harvest Processing: Ensuring Quality and Consistency 08:59 Innovations in Freeze-Drying Cannabis 11:48 The Science Behind Freeze-Drying: A Deeper Dive 14:52 Testing and Refining the Freeze-Drying Process 17:54 The Future of Cannabis Processing: Quality and Efficiency 28:28 Post-Harvest Efficiency and Cost Reduction 30:26 Cultivation Methods and Labor Costs 35:09 Crisis Management and Industry Change 39:22 Market Maturity and Operational Efficiencies 43:00 Future of Cannabis Cultivation 47:04 Innovations in Drying and Curing Processes 52:46 Consumer Perception and Quality Assurance Guest Links: http://cryocure.com/ https://www.linkedin.com/in/greg-baughman-2869b4218/ https://www.linkedin.com/in/edrosenthal-/ https://www.linkedin.com/company/cryocurecannabis/ Our Links: Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The largest payment processor in the world handles cannabis in Canada. In the U.S., they will not touch it. That’s the gap. Aubrey Amatelli left JP Morgan believing that if you followed the rules, aligned with card brand requirements, and structured things correctly, you could build a compliant, stable payment product. Then came Mastercard shutdowns, a failed tech partner that cost six figures, and a stretch where 5,000 dispensaries lost payment access in a matter of weeks. What came out of that was a different approach to building in cannabis. Redundancy is not a feature. It is the product. This week we sit down with Aubrey Amatelli to discuss the following: • JP Morgan to cannabis payments • A failed partner and six figures lost • Why moving from cash to card changes ticket size   Chapters 00:00 Navigating the Cannabis Payment Landscape 02:55 Understanding Payment Processing Challenges 05:57 Building Redundancies in Payment Solutions 09:02 The Impact of Federal Legislation on Payments 12:08 Consumer Education and Payment Solutions 15:03 Product Development and Market Needs 18:02 The Evolving Nature of Cannabis Payments 21:28 Navigating Cannabis Payment Solutions 22:12 The Rise of Cryptocurrency in Alternative Medicine 26:36 The Future of Cannabis Banking and Federal Legalization 30:22 AI's Role in Payment Processing 33:57 Understanding Payment Processing Challenges in Cannabis 37:10 The Importance of Average Ticket Growth   Guest Links https://www.linkedin.com/in/aubreyamatelli/ https://payrio.co/ Our Links Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Politics is a dirty business. Sometimes being feared is the influence you need because access is not the problem. Politicians say "we'll take care of this." Gretchen Gailey has a different approach: stab them in the back, push them down the stairs, and take credit for the fall. It's time to put fear behind cannabis. She spent 20 years on Capitol Hill. She's watched cannabis show up once a year for fly-ins, throw money at the wrong politicians, and wonder why nothing changes. This episode breaks down why incrementalism is the only path, why banking matters more than you think, and why the industry needs to stop picking out curtains when it hasn't built a basement. This week we sit down with Gretchen Gailey: Stab them in the back politics Curtains before basement problem Project Champion playbook   Timestamps: 00:00 - The industry's fundamental misunderstanding about Washington politics 02:35 - Challenges with incrementalism versus desire for rapid change 04:47 - Supporting pro-cannabis politicians like Cynthia Loomis 06:45 - The role of education and public awareness campaigns 10:06 - Building a basic regulatory foundation: banking, safe products, and rescheduling 13:23 - The limitations of state-led models and the need for federal coordination 15:50 - The importance of transparency and federal standards for consumer safety 18:43 - The influence of political operatives and the importance of direct advocacy 22:51 - Using industry tools and data to inform policy and educate policymakers 26:15 - The significance of Congressional engagement and how to make cannabis an urgent issue 30:10 - The importance of political will and executive orders in advancing reform 34:40 - The disconnects within Washington and how industry can better influence policy 37:19 - Opportunities in leveraging symbolism like Veterans issues and Congressional events 41:14 - The disconnect between access and influence, and how to effectively make the case 44:40 - The necessity of creative strategies, public pressure, and celebrity involvement 50:21 - Successful stories: case of Cory Booker and the impact of direct constituent advocacy 52:16 - Final thoughts: how to stay engaged and educate the industry and policymakers Summary:  In this episode, Gretchen Gailey shares over 20 years of experience navigating Washington's complex cannabis legislation. We explore how industry players can effectively engage with policymakers, the importance of foundational regulations, and strategies to accelerate federal progress on cannabis reform. Guest Links: https://www.linkedin.com/in/gretchengailey https://projectchampion.org/ https://x.com/GretchenGailey Our Links Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Investing in cannabis requires a split personality. Everyone thinks they're early. Dan McDermitt has been trading the sector for 15 years — through the Canadian boom, the Biden promise, and the slow bleed that followed. His take: if you've been through multiple pump-and-dump cycles, you're not early anymore. You're just still here. This is a masterclass in separating trader psychology from fundamental conviction. Dan explains why he keeps a small position just to stay seated, why he already knows he'll sell early on the next catalyst, and why the moment everybody's talking about cannabis on Wall Street Bets is the moment you size up — not before. This week we sit down with Dan McDermitt: The "I'm early" delusion Why traders sell early Catalyst stacking thesis MSOS mechanics breakdown Chapters 00:00 The Catalyst Dilemma in Cannabis 03:03 Trading Strategies and Market Positioning 05:48 Understanding Trader vs. Fundamentalist Perspectives 08:46 The Unique Nature of MSOS Trading 11:51 Market Dynamics and Trading Psychology 15:03 The Role of Uplisting and Rescheduling 18:08 Long-Term Perspectives in a Volatile Market 21:04 Risk Management and Trading Mindset 23:51 The Impact of AI on Trading Strategies  Summary In this conversation, Bryan Fields and Dan McDermitt discuss the current state of the cannabis market, focusing on the challenges and opportunities within the sector. They explore the impact of potential rescheduling and uplisting on cannabis stocks, the differences between trading and fundamental analysis, and the unique trading dynamics of MSOS. Dan shares insights on risk management, trading psychology, and the influence of AI on trading strategies, emphasizing the importance of adapting to market conditions while maintaining a disciplined approach. Guest Links: https://x.com/ChartGuys https://www.instagram.com/chartguys/ https://www.youtube.com/@ChartGuys https://www.chartguys.com/ Our Links Bryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter Extraction Teams: Want to cut costs and get more out of every run? Unlock hidden revenue by extracting more from the same input—with Newton Insights. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. The Dime is a top 5% most shared  global podcast The Dime is a top 10 Cannabis Podcast  The Dime has a New Website. Shhhh its not finished. 🎥 YouTube:  The Dime 📸 Instagram:  The Dime https://www.newton-insights.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.